右泛醇口腔凝胶用于临终患者口干管理：一项初步研究
Dexpanthenol mouth gel for the management of dry mouth in hospice patients: A pilot study.
文献信息
| PMID | 42803151 |
|---|---|
| 原文 | 在 PubMed 查看原文 ↗ |
| 发表日期 | 2026 |
| 作者 | Nina Stoks |
| 作者单位 | Center of Expertise in Palliative Care, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, The Netherlands. |
| 期刊 | Palliative medicine |
| SCI 分区 | Q1 |
| IF | 5.5 |
| 研究类型 | 临床研究 · 临床 |
| 所属专科 | 咽喉科 |
中文摘要
背景： 口干影响超过80%的临终患者，导致不适、吞咽困难和生存质量下降。现有治疗往往耐受性差或作用时间短。一种右泛醇口腔凝胶被开发用于临终关怀；然而，由于患者被认为脆弱以及工作人员研究经验有限，评估研究面临挑战。
目的： 评估在临终患者中评价右泛醇口腔凝胶的研究程序的可行性。
设计： 一项混合方法横断面初步研究，于2022年11月至2024年3月在荷兰的14家临终关怀机构分两个阶段进行。
地点/参与者： 纳入估计预期寿命<3个月且自感口干的患者；排除患有粘膜炎的患者。参与研究的临终关怀机构中的医疗保健提供者也参与了研究。
结果： 第一阶段入组28名患者；26名开始，14名在第5天前退出。第二阶段入组49名，分析42名，28名（66.7%）完成研究。失访率为33.3%，主要由于疾病（64%）。医疗保健提供者（n=24）报告了清晰度（95%）和任务可管理性（62%）。大多数患者报告负担低（81%）、信息清晰（97%），60%希望继续使用口腔凝胶。在使用右泛醇口腔凝胶期间，口干（p<0.001）和嘴唇干燥（p<0.001）减少；说话能力（p=0.026）和味觉（p=0.018）随时间改善。
结论： 这项可行性研究表明，在临终关怀机构中，每日应用的三天方案对患者和医疗保健提供者是可行且可接受的。右泛醇口腔凝胶被良好接受，并与几种口腔症状的减轻相关。
英文摘要
BACKGROUND: Dry mouth affects over 80% of hospice patients, resulting in discomfort, swallowing difficulties, and a reduced quality of life. Existing treatments are often poorly tolerated or short acting. A Dexpanthenol mouth gel was developed for hospice use; however, evaluation research is challenged by perceived patient vulnerability and limited research experience among staff.
AIM: To assess the feasibility of study procedures for evaluating Dexpanthenol mouth gel in hospice patients.
DESIGN: A mixed-method cross-sectional pilot study was conducted at 14 hospices in two phases in the Netherlands from November 2022 to March 2024.
SETTING/PARTICIPANTS: Patients with an estimated life expectancy < 3 months who perceived dry mouth were included; patients with mucositis were excluded. Healthcare providers working at participating hospices were involved in the study.
RESULTS: Phase 1 enrolled 28 patients; 26 started, with 14 dropping out before day 5. In Phase 2, 49 were enrolled, 42 analysed, and 28 (66.7%) completed the study. Attrition was 33.3%, mainly due to illness (64%). Healthcare providers (n = 24) reported clarity (95%) and task manageability (62%). Most patients reported low burden (81%), clear information (97%), and 60% wishing to continue using the mouth gel. Dry mouth (p < 0.001) and dry lips (p < 0.001) decreased; speaking ability (p = 0.026) and taste (p = 0.018) improved over time during use of Dexpanthenol Mouth gel.
CONCLUSION: This feasibility study shows that a three-day protocol with daily application is feasible and acceptable for patients and healthcare providers in hospice settings. The Dexpanthenol mouth gel was well accepted and associated with reductions in several oral symptoms.